Inovio Pharmaceuticals Inc.
INO | NASDAQ
$1.28
+$0.04 (+3.23%)
Sep 22, 2026, 12:41 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 65.34K | 217.76K | 832.01K | 10.26M | 1.77M | 7.41M |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 65.34K | 217.76K | 832.01K | 10.26M | 1.77M | 7.41M |
Operating Income | -86.82M | -112.4M | -143.94M | -267.57M | -301.22M | -124.08M |
Interest Income | 2.42M | 4.77M | 8.13M | 4.78M | 3.36M | 3.31M |
Pretax Income | -84.95M | -107.25M | -135.12M | -279.82M | -303.66M | -167.47M |
Net Income | -84.95M | -107.25M | -135.12M | -279.82M | -303.66M | -166.41M |
Selling & General & Admin | 32.68M | 37M | 47.58M | 90.19M | 53.75M | 37.25M |
Research & Development | 54.21M | 75.62M | 86.68M | 187.65M | 249.24M | 94.25M |
Other Expenses | n/a | n/a | 10.51M | n/a | n/a | n/a |
Operating Expenses | 86.89M | 112.62M | 144.77M | 277.84M | 302.99M | 131.49M |
Interest Expense | n/a | 177.83K | 1.22M | 1.25M | 1.94M | 8.7M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 86.89M | 112.62M | 144.77M | 277.84M | 302.99M | 131.49M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 46.89M | 27.16M | 22.17M | 19.89M | 17.4M | 12.93M |
Shares Outstanding (Diluted) | 46.89M | 27.16M | 22.17M | 19.89M | 17.4M | 12.93M |
EPS (Basic) | -1.81 | -3.95 | -6.09 | -14.07 | -1.42 | -1.07 |
EPS (Diluted) | -1.81 | -3.95 | -6.09 | -14.07 | -1.42 | -1.07 |
EBITDA | -81.96M | -103.95M | -130.39M | -270.9M | -296.56M | -149.56M |
EBIT | -84.95M | -107.08M | -133.89M | -276.4M | -301.29M | -154.19M |
Depreciation & Amortization | 2.99M | 3.13M | 3.5M | 5.5M | 4.73M | 4.63M |
Add to Watchlist
Select watchlists to add or remove INO